| Document |
Document Title |
|
WO/2011/077711A1 |
Disclosed is a novel 2-pyridone derivative represented by general formula (1), which has both angiotensin II receptor antagonist activity and PPAR-γ activating activity and is useful as a prophylactic and/or therapeutic agent for cardio...
|
|
WO/2011/072509A1 |
A progesterone formulation composition and the preparation method thereof are disclosed. The composition is composed of progesterone oil content prepared from progesterone, non-polar solvents and solubilizers and encapsulating materials....
|
|
WO/2011/073297A1 |
This invention relates to novel tetrazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of dise...
|
|
WO/2011/073298A1 |
This invention relates to novel tetrazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of dise...
|
|
WO/2011/075056A1 |
The invention relates to a protein composition which upon ingestion by a healthy person, with a normal fasting insulin level between 3.0-8.0 μU/L, increases the insulin level to at most 20.0 μU/L. The invention may be in the shape of a...
|
|
WO/2010/144502A9 |
|
|
WO/2011/069794A1 |
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indica...
|
|
WO/2011/069796A1 |
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and i...
|
|
WO/2011/069799A1 |
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or ...
|
|
WO/2011/069797A1 |
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and i...
|
|
WO/2011/069795A1 |
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or ...
|
|
WO/2011/069798A1 |
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and i...
|
|
WO/2011/069038A2 |
This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase rece...
|
|
WO/2011/068171A1 |
Provided are compounds having prophylactic and/or therapeutic effect on chronic rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn diseases and ulcerative colitis, autoimmune diseases typified by psoriasi...
|
|
WO/2011/064753A1 |
The invention relates to the hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3, 5-Dihydroxy-3-(2-hydroxy-acetyl)-3a, 6-dimethyl- 7-oxo-dodecahydro-cyclo- penta[alpha]naphthalen-6-yl] -propionic acid, designated as DeinaÂ...
|
|
WO/2011/064769A1 |
Certain embodiments disclosed herein relate to uses, methods and compositions comprising azapirones for the treatment of hot flashes. In specific embodiments, the compositions comprise buspirone as the active ingredient. The invention fu...
|
|
WO/2011/059021A1 |
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...
|
|
WO/2011/057382A1 |
Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. or a stereoisomer thereof, or a pharmaceuti...
|
|
WO/2011/060019A1 |
The present invention relates to the compound of the formula: Formula (I); to pharmaceutical compositions comprising the compound of Formula (I); and to methods for treating or preventing hypogonadism, osteoporosis, osteopenia, sarcopeni...
|
|
WO/2011/059839A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2011/056389A2 |
A method makes an artificial micro-gland by taxis. A monodisperse multiple emulsion is produced with a first fluid; a second fluid confined within the first fluid; a third fluid within the second fluid. Interfaces between fluids permit l...
|
|
WO/2011/055550A1 |
Disclosed is a therapeutic agent for cellular immune diseases, which comprises a substance capable of inhibiting the binding between a Neuropilin-1/Plexin-A1 hetero receptor and Sema3A as an active ingredient. The substance is, for examp...
|
|
WO/2011/056390A2 |
A method is disclosed for making an artificial micro-gland having a continuous anisotropic membrane of two or more types of living cells. A first step includes forming a carrier fluid in a microchannel in a laminar flow of two distinct f...
|
|
WO/2011/050742A1 |
Three new crystalline forms of Agomelatine, their preparation methods and the pharmaceutical compositions containing them and their preparation use of drug used for curing the diseases of central nervous system are provided. These three ...
|
|
WO/2011/053821A1 |
The present invention provides novel conformationalIy- defined macrocyclic compounds of formula (I) that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and s...
|
|
WO/2011/048350A1 |
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the pati...
|
|
WO/2011/047837A2 |
The invention relates to an intermediate, which can be obtained by means of melt-extruding (i) cinacalcet or a pharmaceutically acceptable salt thereof, comprising (ii) a matrix former and oral forms of administration, in particular tabl...
|
|
WO/2011/047515A1 |
Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical sym...
|
|
WO/2011/047262A2 |
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
|
|
WO/2011/044307A1 |
This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compoun...
|
|
WO/2011/042475A1 |
The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt there...
|
|
WO/2011/042477A1 |
The invention provides a compound of formula (I) wherein G is a pyrrole or imidazole moiety and R4, R5, R6, R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt ...
|
|
WO/2011/039096A1 |
The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut pepti...
|
|
WO/2011/038207A1 |
The present invention relates to sulfonic acid containing compounds that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds...
|
|
WO/2011/036651A1 |
The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleo...
|
|
WO/2011/034834A2 |
Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These composition...
|
|
WO/2011/030929A1 |
Use of a compound represented by formula (I), a salt thereof or a solvate of the same for inhibiting type 3 17β-hydroxysteroid dehydrogenase, and so on.
|
|
WO/2011/030927A1 |
Use of a compound represented by formula (I), a salt of the compound, or a solvate of the compound or the salt for inhibiting type-3 17β-hydroxysteroid dehydrogenase; and others.
|
|
WO/2011/029547A2 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2011/029359A1 |
The present invention discloses compounds which can lower the activity of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) reductase and/or improve the activity of 11β-HSD1 oxidase, as well as the uses of said compounds in manufacturing ...
|
|
WO/2011/028811A2 |
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
|
|
WO/2011/029088A2 |
The invention provides processes for the preparation of pure raloxifene or its salts, involving hydrolyzing 6-methylsulfonyloxy-2-[(4-methylsulfonyloxy)-phenyl]-3-[4(2-
(piperidinyl)ethoxy)benzoyl]benzothiophene hydrochloride, using an a...
|
|
WO/2011/027119A1 |
A medicament for treating inflammation of human or animal body tissues contains a steroid, typically a corticosteroid, in combination with a non-steroidal anti-inflammatory drug (NSAID), typically a cyclooxygenase (COX-1 or COX-2) inhibi...
|
|
WO/2011/023703A1 |
The present application relates to novel heterocyclic-substituted 1-carboylmethyl-3-aryl-1,2,4-triazol-5-ones, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases, ...
|
|
WO/2011/023769A1 |
Provided is a composition which comprises yeast cells treated with, or grown from yeast cells treated with electromagnetic waves in the range of 30 GHz to 300 GHz. Said composition may be used for the treatment of neurodegenerative disea...
|
|
WO/2011/021678A1 |
Disclosed are: a fused heterocyclic compound having excellent medical activities including a p38 MAPK-inhibiting activity and a TNF-α production-inhibiting activity; a medicinal agent comprising the compound; and others. Specifically di...
|
|
WO/2011/022596A2 |
Processes for preparing bazedoxifene and its pharmaceutically acceptable salts, substantially free from process related impurities and process intermediates.
|
|
WO/2011/021645A1 |
Provided is a bicyclic urea derivative that inhibits soluble epoxide hydrolase (sEH), said bicyclic urea derivative represented by formula (I), or a pharmacologically permitted salt thereof. In the formula, R1 represents a C3-9 cycloalky...
|
|
WO/2011/016459A1 |
Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)
|
|
WO/2011/015984A1 |
The subject of the invention is an orally administerable pharmaceutical preparation containing a combination of biotechnologically produced human recombinant insulin and/or modified insulin or an analogue and/or derivative thereof, a pro...
|
